One drop. All day. The first
Indications and usage

BROMDAY (bromfenac ophthalmic solution) 0.09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Dosage and administration

Instill one drop into the affected eye(s) once daily beginning 1 day prior to surgery, continued on the day of surgery and through the first 14 days post-surgery.

Warnings and precautions
  • Sulfite allergic reactions
  • Potential for cross-sensitivity
  • Corneal effects including keratitis
  • Slow or delayed healing
  • Increase bleeding of ocular tissues
  • Contact lens wear
Adverse reactions

The most commonly reported adverse reactions in 2-7% of patients were abnormal sensation in eye, conjunctival hyperemia and eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache, and iritis.

Bromday

The first once daily ophthalmic NSAID for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.1

Download information sheet with full prescribing information
Bromday(R): Potency and penetration with qd efficacy 1-4
CLICK PLUS OR MINUS TO EXPAND/CONTRACT

Clinically significant reduction in inflammation as early as Day 8 of clinical
studies (10 drops)4

Reduction in mean SOIS* at each visit
*Summed ocular inflammation score (SOIS).
†Integrated data.
**Statistically significant (P<0.0001).
Integrated Data (4 clinical studies) by Day 154  
Zero to trace inflammation 79% 42%
Complete clearance of inflammation 51% 27%
Pivotal Trials (2 clinical studies) by Day 156
Zero to trace inflammation 74% 40%
Complete clearance of inflammation 46% 26%
STUDY DESIGN
  • Clinical efficacy was evaluated in four randomized, double-masked, clinical trials in which subjects requiring cataract surgery were dosed with one drop per eye starting the day before surgery, day of surgery and continuing for 14 days. The primary endpoint was clearing of ocular inflammation by day 15. An additional efficacy endpoint was the number of patients who were pain free on day 1 after cataract surgery.3

Integrated study data showed low discontinuation rates for BROMDAY4

Lack of Efficacy
  • Only 2.9% of BROMDAY patients vs 32.7% of placebo patients withdrew due to lack of efficacy by Day 15 (P<0.0001)4

Adverse Events
  • Only 5.1% of BROMDAY patients vs 15.6% of placebo patients discontinued due to adverse events (P<0.0001).5
Bromday(R): Comfort and compliance with QD efficacy
CLICK PLUS OR MINUS TO EXPAND/CONTRACT

In clinical trials, most treated patients were pain free at day 144

Integrated Data (4 clinical studies)
  • 84% of patients on BROMDAY, and 67% of patients on placebo4

Pivotal Trials (2 clinical studies)
  • 87% of patients on BROMDAY, and 65% of patients on placebo6

Ocular comfort demonstrated in BROMDAY-treated eyes4

  • Throughout the duration of the 4 clinical studies, patients treated with BROMDAY reported less eye pain, tearing, foreign body sensation, and photophobia compared to those treated with placebo4

  • Low occurrence of itching, eye discharge, and haziness4

One drop lasts all day3

  • A full course of treatment for BROMDAY is only 16 drops vs other ophthalmic NSAIDs, which may require up to 56 drops3,8-11

Total NSAID drops for indicated length of treatment

ADVERSE REACTIONS

The most commonly reported adverse reactions in 2-7% of patients were abnormal sensation in eye, conjunctival hyperemia and eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache, and iritis.

Bromday logo